Artal Group’s iTeos Therapeutics ITOS Stock Holding History

Artal Group’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-400,000	Closed	-$4.38M	–	117
2023 Q4	$4.38M	Hold	400,000	–	–	0.15%	57
2023 Q3	$4.38M	Hold	400,000	–	–	0.19%	60
2023 Q2	$5.3M	Hold	400,000	–	–	0.16%	64
2023 Q1	$5.44M	Hold	400,000	–	–	0.32%	59
2022 Q4	$7.81M	Hold	400,000	–	–	0.44%	49
2022 Q3	$7.62M	Hold	400,000	–	–	0.33%	50
2022 Q2	$8.24M	Hold	400,000	–	–	0.44%	43
2022 Q1	$12.9M	Sell	400,000 -144,047	-26%	-$5.23M	0.54%	42
2021 Q4	$25.3M	Sell	544,047 -450,000	-45%	-$15M	0.69%	37
2021 Q3	$26.8M	Hold	994,047	–	–	0.6%	39
2021 Q2	$25.5M	Sell	994,047 -100,000	-9%	-$2.38M	0.52%	42
2021 Q1	$37.4M	Hold	1,094,047	–	–	0.66%	35
2020 Q4	$37M	Hold	1,094,047	–	–	0.79%	34
2020 Q3	$27M	Buy	+1,094,047	New	+$29.4M	0.66%	37

Other funds holding ITOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Artal Group's ITOS Position: Q1 2024 in Review

Artal Group sold out of iTeos Therapeutics (ITOS) in Q1 2024, closing a stake of 400,000 shares — an estimated $4.38M sold.

Artal Group first reported a position in ITOS in Q3 2020 and held it in 14 quarters. The position peaked at $37.4M in Q1 2021. 135 funds tracked by Wall St. Rank hold ITOS as of Q1 2024.

Artal Group reported no remaining iTeos Therapeutics position as of Q1 2024 after selling out during the quarter.
Artal Group sold 400,000 iTeos Therapeutics shares in Q1 2024, an estimated $4.38M.
Artal Group first reported a position in iTeos Therapeutics in Q3 2020 and held it in 14 quarters.
Artal Group's iTeos Therapeutics position peaked at $37.4M in Q1 2021.
135 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q1 2024.

Based on Artal Group's 13F filing for Q1 2024, filed 13 May 2024.